Definition Packaging Pharmaceutical Companies 
European Pharmaceutical Review
JULY 5, 2023
The long-awaited PDA TR 43 report provides an approach to a quality decision-making process and represents best practices for the identification and classification of visual nonconformities for (empty) glass containers as pharmaceutical product packaging.
European Pharmaceutical Review
MARCH 14, 2023
This concerns the quantity of the medicinal product in the packaging, ie, the increase or decrease in the number of units of the product in the outer packaging according to local demands and its labelling, including the leaflet, which should be in the language of the country into which the product is imported.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JANUARY 13, 2025
If we want to lead the way in green innovation and show that the UK is open for business, we need a broader definition and recognition of innovation. Sustainable pharma packaging: breaking down the barriers to adoption Over two years it resulted in approximately 52,000 inhalers being returned, equating to approximately 305 tonnes of CO 2.
European Pharmaceutical Review
DECEMBER 21, 2022
All traditional small molecule pharmaceuticals include carbon building blocks – by definition, organic materials – which are then transformed via modern synthetic chemistry to assemble the complex and highly variable skeletons that the final target structures demand. However, it is already clear that the investments will be gargantuan.
European Pharmaceutical Review
OCTOBER 17, 2022
Sanofi has signed definitive agreements with Adragos Pharmaceutical, a German contract development and manufacturing organisation (CDMO), for the sale of its pharmaceutical manufacturing site in Kawagoe, Japan. The French pharmaceutical company will also enter into a long-term supply agreement with the CDMO.
pharmaphorum
APRIL 11, 2022
The answer to this question comes back to our definition of value. If we are to move towards a value-based healthcare system, then we must utilise the power of both clinical trials data and real-world evidence, to produce the best possible data package for regulatory submissions. About the author.
ISPE
NOVEMBER 2, 2022
Applying what has been learned over the last three years to update pharmaceutical companies’ approaches to development and implementation is key as the industry crafts its strategies in an increasingly digital and global environment. President, U.S. Business Unit and U.S. Country Head.
Expert insights. Personalized for you.
96 
Let's personalize your content